Abstract
As selective serotonin reuptake inhibitors (SSRIs) are among the most commonly prescribed medications in autism, we aimed to determine whether targets for SSRIs are differentially affected in three cortical areas in children and adults with autism compared to neurotypical individuals. Utilizing a large cohort of postmortem brain tissue (n = 14 – 19 per group), saturation ligand binding assays were conducted on sections from the anterior cingulate cortex (ACC), posterior cingulate cortex, and fusiform gyrus (FG). Specific binding to the 5-HT transporter (5-HTT) as well as to 5-HT₂ and 1A receptors (5-HT₂, 5-HT₁A) was quantified in superficial and deep layers of each region using the ligands [³H]-citalopram (5-HTT), [³H]-ketanserin (5-HT₂), and [³H]-8-OH-DPAT (5-HT₁A). A Welch’s t-test was utilized to compare receptor densities (Bₘ₉₉₉), revealing a statistically significant decrease in 5-HTT within the ACC of the entire autism cohort. There was also a decrease in 5-HT₂ receptor density in the ACC in the adult cohort, but not in child postmortem autism cases as compared to controls. Comparing linear regression lines of Bₘ₉₉₉ values plotted against age, shows a significantly lower intercept for 5-HTT in autism (p = 0.025). 5-HT₂ density increases with age in control cases, whereas in autism there is a decrease with age and significantly different slopes between regression lines (p = 0.032). This suggests a deficit in 5-HTTT within the ACC in individuals with autism, while decreases in 5-HT₂ density are age-dependent. There were no differences in receptor densities in the posterior cingulate cortex or FG in autism and no differences in ligand affinity (Kₐ) across all regions and ligands examined. Keywords: anterior cingulate cortex, autism, selective serotonin reuptake inhibitors (SSRIs), serotonin receptors (5-HT₂, 5-HT₁A), serotonin transporter (5-HTT).

J. Neurochem. (2019) 151, 642–655.

Peripheral hyperserotonemia was the earliest demonstrated neurochemical change in individuals with autism spectrum disorders (ASD) (Schain and Freedman 1961) and has since become the best replicated biomarker, as recent meta-analyses conclude that hyperserotonemia is present in 25–45% of the autism population (Gabriele et al. 2014; Chen et al. 2017; Eissa et al. 2018). Furthermore, whole blood maternal serotonin levels during pregnancy are associated with altered cognitive abilities and core neurodevelopmental outcomes in offspring with ASD (Montgomery et al. 2018).

In the last decade, attention also has been directed toward the study of central serotonin levels during pregnancy are associated with altered cognitive abilities and core neurodevelopmental outcomes in offspring with ASD (Montgomery et al. 2018).

Received February 11, 2019; revised manuscript received June 17, 2019; accepted July 12, 2019.

Address correspondence and reprint requests to Gene J. Blatt, Program on Neuroscience, Hussman Institute for Autism, 801 W. Baltimore Street Suite 301, Baltimore, MD 21201, USA. E-mail: gblatt@hussman-autism.org

Abbreviations used: [³H], tritiated; 5-HT, 5-hydroxytryptamine (serotonin); 5-HT₁A, serotonin 1A receptor; 5-HT₂, serotonin 2 receptor; 5-HT₂A, serotonin 2A receptor; 5-HT₃, serotonin transporter; ACC, anterior cingulate cortex; ADHD, attention-deficit/hyperactivity disorder; ADI-R, autism diagnostic interview-revised; ASD, autism spectrum disorders; Bₘ₉₉₉, receptor density; CDC, Centers for Disease Control and Prevention; FG, fusiform gyrus; fMRI, functional magnetic resonance imaging; Kₐ, equilibrium dissociation constant; nCi, nanocuries; PCC, posterior cingulate cortex; PET, positron emission tomography; PMI, postmortem interval; SLC6A4, serotonin transporter gene; SPECT, single photon emission computed tomography; SSRIs, selective serotonin reuptake inhibitors.
maturation, as well as a variety of other neural processes (for review see: Garbarino et al. 2018). The usage of drugs targeting 5-HTT has increased in an effort to treat symptoms of depression and/or other core symptoms in a variety of neuropsychiatric disorders. In a Centers for Disease Control and Prevention report, between 2011 and 2014, 12.7% of persons over 12 years of age had used antidepressant medications in the previous month, 68% took these medications for 2 years or more, while 25% took them for 10 years or more (Pratt et al. 2017).

Selective serotonin reuptake inhibitors (SSRIs) have been effective in treating patients with major depressive, anxiety and obsessive compulsive disorders and have been widely prescribed to individuals with autism for the treatment of repetitive behaviors (King and Bostic 2006), as 21–32% of children with ASD are prescribed one or more antidepressant medications (Langworthy-Lam et al. 2002; Aman et al. 2003; Oswald and Sonenklar 2007). Pharmacotherapeutic treatment for individuals with autism has been largely off-label (Oswald and Sonenklar 2007) and often not directed toward core symptoms of the condition (Gibbs 2010). In a seminal clinical trial by King et al. (2009), citalopram hydrobromide, an SSRI that primarily targets 5-HTT, was administered to 149 children with ASD aged 5–17 years for 12 weeks from six academic institutions. Instead of seeing significant improvement in symptoms and/or behavior, the citalopram hydrobromide group experienced adverse effects of the drug, including increased energy level and hyperactivity, insomnia, reduced concentration, impulsiveness, and stereotyped behaviors. Recently, a case report in which four children 6–12 years old with ASD were given low doses of the SSRI fluoxetine found improvement in attention-deficit/hyperactivity disorder-like symptoms, irritability and/or self-injurious behavior (Lucchelli and Bertschy 2018). Previously, Hollander et al. (2012) found improvement in repetitive behaviors in adult ASD subjects who were administered fluoxetine while McDougle et al. (1996), in a clinical trial using the SSRI fluvoxamine, reported improvement in aggressive behavior in adult ASD patients. However, a Cochrane Review including 320 participants concluded there is no evidence for SSRIs as effective treatments for autism in children, but there is limited evidence for effectiveness in adults (Williams et al. 2013). These and other studies suggest that there are differential effects depending on the specific dose-dependent SSRI administered, with citalopram being the least effective in ameliorating or modulating autism-related behaviors.

Nevertheless, there is substantial evidence that 5-HT systems are altered in ASD in both humans and in animal models (for review see: Muller et al. 2016). Many individuals with ASD and some of their family members have increased blood 5-HT levels (Schain and Freedman 1961; Cook and Leventhal 1996; Lam et al. 2006; Gabriele et al. 2014) and genetic variation in 5-HTT in some individuals with autism has been reported (Yonan et al. 2003; Devlin et al. 2005; Sutcliffe et al. 2005; Kistner-Griffin et al. 2011). Positron emission tomography (PET) imaging studies have demonstrated abnormal 5-HT synthesis in brain regions in autism (Chugani et al. 1997; Chugani et al. 2001; Chandana et al. 2005) and a polymorphism in the gene for the serotonin transporter (SLC6A4) has been associated with increased cerebral cortex grey matter volume in children with ASD (Wassink et al. 2007).

These early clinical, imaging, and genetic studies demonstrated 5-HT alterations in the autism brain, supported the use of 5-HT as a biomarker and suggested the potential for novel biomarkers to be found in different 5-HT receptor subtypes, which led to several imaging studies that focused primarily on high-functioning individuals with autism. A PET imaging study of a high-functioning autism cohort \((n = 20, 18–26 \text{ years of age})\) revealed decreased 5-HTT binding in the anterior cingulate cortex (ACC), posterior cingulate cortex (PCC) and thalamus, which was associated with behavioral changes, including impairment of social cognition and repetitive/obsessive actions and interests (Nakamura et al. 2010). Makkoen et al. (2008) used single photon emission computed tomography on a small group of high-functioning children and adolescents and found decreased 5-HTT binding in the medial frontal lobe, especially in the adolescent cohort, whereas 5-HTT binding in the midbrain and temporal lobe was normal. In another imaging study, Murphy et al. (2006) utilized the ligand \(^{123}\text{I}-5-	ext{I-R91150}\) that shows selectivity for 5-HT\(_2\) receptors and reported significant binding decreases associated with social communication deficits. Additionally, parents of children with ASD have been reported to have significantly decreased cortical 5-HT\(_2\) receptor binding, with a negative correlation to their platelet 5-HT levels using PET imaging (Goldberg et al. 2009).

In contrast to high-functioning autism, there is a paucity of investigations that include idiopathic autism cases, making it difficult to generalize potential pharmacotherapies toward affected receptors across the autism spectrum. In one of the few studies of idiopathic autism, Azmitia et al. (2011) utilized immunocytochemistry in postmortem autism and neurotypical control cases 2–29 years to label serotonergic fibers in the forebrain cortical white matter and their projections into the temporal cortex. These investigators identified an increased number of 5-HT axons in the autism group, leading to the conclusion that physicians should use caution in prescribing SSRIs to children. These authors also postulated that the increased number of 5-HT axons could have profound effects on 5-HT receptor subtypes, including the presynaptic 5-HT\(_{1A}\) receptors and the abundant 5-HT\(_{2A}\) receptors, thus affecting synaptogenesis and ultimately function.

However, there are very few studies analyzing 5-HT receptor differences within the postmortem brain of...
individuals with autism. Our initial findings based on single concentration ligand binding studies in young adults with ASD provided strong evidence for alterations in brain 5-HT systems in autism due to the high sensitivity of autoradiography methods, with reductions in density of 5-HT1A and 5-HT2A receptors in the PCC and fusiform gyrus (FG), but no change in binding to the transporter 5-HTT (Oblak et al. 2013). This suggested that pharmacotherapies targeted toward affected 5-HT receptor subtypes identified within different individuals may lead to improved therapeutic outcomes.

We thus aimed to expand on our initial single concentration ligand study (Oblak et al. 2013) by increasing the cohort size and comparing multiple concentrations of three 5-HT ligands in three cortical regions within ASD cases that span a range of severity in diagnosis. In addition to the PCC and FG, we included the ACC, which had not been evaluated in the previous study. Here, we perform multiple concentration saturation binding assays in a cohort of human postmortem brain tissue from individuals with idiopathic autism as compared to age-matched neurotypical control brains. This design allows for determination between a change in receptor density (Bmax) and/or a change in ligand affinity (Kd), which might arise due to post-translational modification of receptors, receptor oligomerization, or association of receptors with modulatory proteins (Nichols and Nichols 2008). 5-HT1A and 5-HT2 receptors, as well as the transporter 5-HTT, were quantified in both superficial and deep laminar layers in the ACC, PCC and FG. This larger cohort allowed for separation of cases based on age (adults > 16 years and children/adolescents ≤ 16 years) to mimic clinical trials that found differential age-related results with SSRI use.

In one of the largest postmortem autism studies to date, our results indicate alterations in the 5-HT system within the adult ACC. The ACC is one of the most consistently reported abnormal cortical regions in behavioral, imaging, and pathological studies in autism (Bauman and Kemper 1985; Bailey et al. 1998; Simms et al. 2009; Forde et al. 2018) and plays fundamental roles in cognitive processes such as motivation, decision making, learning, cost-benefit calculation, as well as conflict and error monitoring (Shackman et al. 2011; Holroyd and Yeung 2012; Rushworth et al. 2012; Shenhav et al. 2013; Ullsperger et al. 2014; Holroyd and McClure 2015; Verguts et al. 2015; Laubach et al. 2015; Kolling et al. 2016; Apps et al. 2016). An emerging role for the ACC in social cognition, particularly tracking the motivation of others (for review see: Apps et al. 2016), may be especially relevant in the context of ASD as it is thought that autistic individuals lack social motivation (Mundy and Neal 2000; Dawson et al. 2005; Schultz 2005; Chevallier et al. 2012). Therefore, the ACC may represent a vulnerable area in ASD, which has been shown to have relevance to ASD specific behaviors.

Materials and methods

Postmortem tissue

Human postmortem brain tissue was obtained from the University of Maryland Brain and Tissue Bank, a brain and tissue repository of the NIH Neurobiond, and from the Harvard Brain and Tissue Resource Center of the Autism Tissue Program, which is now Autism BrainNet. Case demographics are provided in Table 1. Fresh frozen tissue blocks from the left hemisphere of three cortical regions including the ACC (n = 19 control, n = 18 autism), PCC (n = 18 control, n = 19 autism), and FG (n = 18 control, n = 14 autism) were sectioned coronally at 20 µm on a cryostat and kept frozen at −80°C. There were no statistically significant differences in total case ages (p = 0.14) or postmortem interval (p = 0.23) between autism and control cases using a Welch’s t-test. All autism cases had confirmed diagnoses through the autism diagnostic interview-revised (ADI-R) scores and/or received a clinical diagnosis of autism from a licensed psychiatrist. Ten autism cases had at least one seizure reported and seven had reported medications (Table 1).

As this research did not involve live human subjects, Institutional Review Board approval and informed consent was not necessary. However, the University of Maryland Brain and Tissue Bank is overseen by Institutional Review Board protocol number HM-HP-00042077. This study was not pre-registered.

Satisfaction ligand binding assays

Three tritiated [3H] ligands (Perkin Elmer, Boston, MA, USA) including ketanserin [NET7910 (2015)] (specific activity (SA) = 47.3 Ci/mmol), citalopram [NET1039 (2015)] (SA = 82.1 Ci/mmol), and 8-OH-DPAT [NET929 (2015)] (SA = 146 Ci/mmol) were utilized as outlined in Table 2. All tissues included in each assay were processed under the same conditions at seven different concentrations that spanned 0.51 to 139nM in order to obtain saturation binding curves for each ligand (Oblak et al. 2011). Two thawed 20 µm sections from each case were used to quantify total binding at each concentration of ligand and one section from each case was exposed to the ligand as well as 100 µM of a displacer (imipramine hydrochloride AAJ6372306, Fisher Scientific, Waltham, MA, USA (2016); ritanserin 1955, Tocris Biosciences, Bristol, UK (2016) and serotonin hydrochloride 3547, Tocris Biosciences (2016)) to determine non-specific binding (Table 2), which was subtracted from the total binding to yield specific binding of the ligand to the respective receptor subtype. All tissues went through a pre-incubation in buffer without ligand (5-HT2): 50 mM Tris-HCl (pH 7.4), 4 mM CaCl2, 0.1% ascorbate; 5-HTT: 50 mM Tris-HCl (pH 7.4), 120mM NaCl, 5mM KCl; 5-HT1A; 170 mM Tris-HCl (pH 7.6), 4 mM CaCl2, 0.01% ascorbate) for 30 min before being exposed to the ligand and were then rinsed three times for 5 min in buffer followed by one dip in distilled water and allowed to air-dry overnight. Slides were placed in X-ray cassettes with [3H]-sensitive hyperfilm [Kodak Biomax MR film Z350389; Sigma-Aldrich, St. Louis, MO, USA (2016)] and a [3H] standard [Tritium standards ART0123; American Radiolabeled Chemicals, St. Louis, MO, USA (2015)] then exposed for 3–26 weeks. Films were processed in a darkroom by developing for 3 min in developer [Kodak D19 74200; Electron Microscopy Sciences, Hatfield, PA, USA (2015)], fixed [Kodak Rapidfix 74312;
## Table 1 Postmortem brain donor case demographics.

| Cases         | Diagnosis     | Age | PMI | Gender | Ethnicity          | Cause of Death                              | Brain Bank - Seizure |
|---------------|---------------|-----|-----|--------|--------------------|---------------------------------------------|----------------------|
| Adults >16    |               |     |     |        |                    |                                             |                      |
| 602           | Control       | 27  | 15  | M      | Caucasian          | Accident, multiple injuries                 | UMBTB                |
| 1026          | Control       | 28  | 6   | M      | Caucasian          | Congenital Heart Disease                    | ATP                  |
| 1365          | Control       | 28  | 17  | M      | Caucasian          | Multiple injuries                           | ATP                  |
| 4103          | Control       | 43  | 23  | M      | Caucasian          | Heart attack/disease                        | ATP                  |
| 4104          | Control       | 24  | 5   | M      | African American   | Gun shot to the chest                       | ATP                  |
| 4267          | Control       | 26  | 20  | M      | African American   | Accident                                    | ATP                  |
| 4268          | Control       | 30  | 22  | M      | African American   | Cardiomyopathy (heart attack/disease)       | ATP                  |
| 4271          | Control       | 19  | 21  | M      | African American   | Epiglottis/unknown                          | ATP                  |
| 4272          | Control       | 19  | 17  | M      | Caucasian          | Accident                                    | ATP                  |
| 4275          | Control       | 20  | 16  | M      | Caucasian          | Accident                                    | ATP                  |
| 4345          | Control       | 27  | 19  | F      | Caucasian          | Respiratory failure                         | UMBTB                |
| 4364          | Control       | 27  | 27  | M      | Unknown            | Motor vehicle accident                      | ATP                  |
| 4599          | Control       | 23  | 18  | M      | African American   | Cardiac arrhythmia/anomalous coronary artery | UMBTB                |
| 4605          | Control       | 29  | 17  | M      | African American   | Commotio cordis                             | ATP                  |
| 4916          | Control       | 19  | 5   | M      | Caucasian          | Accident, drowning                          | ATP                  |
| 5321          | Control       | 19  | 12  | F      | Unknown            | Accident                                    | ATP                  |
| 5813          | Control       | 20  | 24  | M      | African American   | Atherosclerotic cardiovascular disease       | UMBTB                |
| 5873          | Control       | 28  | 23  | M      | African American   | Unknown                                     | ATP                  |
| 6004          | Control       | 36  | 18  | F      | African American   | Unknown                                     | ATP                  |
| 1078          | Autism        | 22  | 14  | M      | Caucasian          | Congenital heart disease                    | ATP- Yes             |
| 1401          | Control       | 21  | 20  | F      | Caucasian          | Sepsis                                      | ATP                  |
| 1484          | Autism        | 19  | 15  | M      | English-white      | Burns                                       | ATP                  |
| 1664          | Autism        | 20  | 15  | M      | Unknown            | Drowning                                    | ATP- Yes             |
| 2825        | Autism        | 19  | 9   | M      | Unknown            | Cardiac arrest                              | ATP- Yes             |
| 3845          | Autism        | 30  | 28  | M      | English-white      | Cancer                                      | ATP                  |
| 4099          | Autism        | 19  | 3   | M      | Caucasian          | Drowning                                    | ATP                  |
| 5027          | Autism        | 37  | 26  | M      | African american   | Obstruction of bowel due to adhesion         | UMBTB- Yes           |
| 5574          | Autism        | 23  | 14  | M      | African american   | Pneumonia                                   | UMBTB                |
| 5754          | Autism        | 20  | 29  | M      | Unknown            | Unknown                                     | ATP                  |
| 5771          | Autism        | 27  | 5   | F      | Caucasian          | Undetermined                                | UMBTB- Epilepsy      |
| 5864          | Autism        | 20  | 63  | M      | Caucasian          | Seizure disorder                            | UMBTB                |
| 6337          | Autism        | 22  | 25  | M      | Caucasian          | Aspiration                                  | ATP                  |
| Children/adolescents ≤16 |               |     |     |        |                    |                                             |                      |
| 1714          | Control       | 12  | 22  | M      | African American   | Cardiac arrhythmia                          | UMBTB                |
| 3835          | Control       | 9   | 8   | F      | African American   | Unknown                                     | UMBTB                |
| 4188          | Control       | 16  | 13  | M      | African American   | Gunshot                                     | ATP                  |
| 4274          | Control       | 16  | 15  | F      | Unknown            | Accident                                    | ATP                  |
| 4337          | Control       | 8   | 16  | M      | African American   | Blunt force neck injury                      | UMBTB                |
| 4670          | Control       | 4   | 17  | M      | Caucasian          | Commotio cordis                             | UMBTB                |
| 5170          | Control       | 13  | 20  | M      | African American   | Gunshot wound to chest                      | UMBTB                |
| 5242          | Control       | 15  | 9   | M      | Caucasian          | Cardiac arrhythmia                          | UMBTB                |
| 5334          | Control       | 12  | 15  | M      | Hispanic           | Hanging/ suicide                            | UMBTB                |
| 5376          | Control       | 13  | 19  | M      | Caucasian          | Hanging/suicide                             | UMBTB                |
| 5387          | Control       | 12  | 13  | M      | Caucasian          | Drowning                                    | UMBTB                |
| 5391          | Control       | 8   | 12  | M      | Caucasian          | Drowning                                    | UMBTB                |
| 5408          | Control       | 6   | 16  | M      | African American   | Drowning                                    | UMBTB                |
| 5558          | Control       | 5   | 19  | M      | Caucasian          | Anomalous left coronary artery w/ complications | UMBTB                |
| 1469          | Autism        | 5   | 42  | M      | English-white      | Unknown                                     | ATP                  |
| 2004          | Autism        | 10  | 23  | M      | Asian             | Drowning                                    | UMBTB                |
| 2993          | Autism        | 5   | 4   | M      | English-white      | Acute respiratory distress syndrome          | ATP- Yes             |
| 3871          | Autism        | 5   | 25  | M      | Caucasian-Hispanic | Drowning                                    | UMBTB- Yes           |

(continued)
Electron Microscopy Sciences (2015) for 4 min at 23°C and washed with a stream of water for at least 1 h and air-dried.

Data analysis

Autoradiographs of the tissue sections exposed to film were digitized with a QICAM digital camera (QImaging, Surrey, BC, Canada) and analyzed using MCID Core 7.1 Elite Image analysis system software (InterFocus Imaging Ltd, UK). Calibration of each film with its own [3H] standard allowed for comparisons across films by choosing one representative standard curve and normalizing all other standard curves and images to it within the MCID software (Linton, UK). The standard curves allowed for conversion from optical density to nanocuries per milligram (mg).

Binding in the superficial layers (I—IV) and deep layers (V—VI) of each cortical region (Fig. 1) was sampled with the ribbon tool running along the length of the observable region of interest then converted to femtomoles per mg of protein based on the specific activity of each ligand. The ACC, a limbic cortical area, lacks layer IV, thus superficial sampling in the ACC includes layers I—III. The experimenter was blinded to the diagnosis of the cases during sampling. After background subtraction, these total binding values were plotted against the concentration of ligand and fitted with nonlinear least squares regression to generate saturation binding curves in GraphPad prism 6 to estimate the number of receptors (Bmax) and binding affinity (Kd) of each ligand for each case.

Statistical analyses

Equality of variance was calculated with an F-test, and since many of the autism ligand groups compared to the control groups did not show equality of variance, Welch’s t-tests were performed to determine differences in the number of estimated total receptors (Bmax). Since the statistical distribution of fitted Kd values is log-normal (Delean et al. 1982), averaging, calculation of standard errors, and significance testing were carried out on the negative logarithm of Kd (pKd = −logKd) (Oblak et al. 2009). Student’s t-tests were conducted to compare binding affinity for each ligand in each brain region (Table 3). An assessment of normality was conducted using the Shapiro–Wilk test and both control and autism Bmax and Kd values followed a normal distribution. Regression analyses were carried out in Microsoft Excel (2013) and fitted with trendlines to obtain R2 values. Student’s t-tests were utilized to compare the slope and intercept (elevation) of the trendlines

Table 1 (continued)

| Cases | Diagnosis | Age | PMI | Gender | Ethnicity | Cause of Death | Brain Bank- Seizure |
|-------|-----------|-----|-----|--------|-----------|-----------------|---------------------|
| 3924  | Autism    | 16  | 9   | F      | Portuguese/Spanish | Epilepsy         | UMBTB- Epilepsy     |
| 4334d | Autism    | 11  | 27  | M      | Hispanic  | Acute hemorrhagic tracheobronchitis | UMBTB              |
| 4721  | Autism    | 8   | 16  | M      | African American | Drowning         | UMBTB               |
| 4849  | Autism    | 7   | 20  | M      | African American | Drowning         | UMBTB               |
| 4899e | Autism    | 14  | 9   | M      | Caucasian | Drowning         | UMBTB               |
| 5144  | Autism    | 7   | 3   | M      | Caucasian | Complications of cancer | UMBTB- 1 week before death |
| 5302  | Autism    | 16  | 20  | M      | Caucasian | Diabetic ketoacidosis | UMBTB              |
| 5308  | Autism    | 4   | 21  | M      | Caucasian | Skull fractures   | UMBTB- Disorder     |
| 5565f | Autism    | 12  | 22  | M      | African American | Seizure disorder, complications | UMBTB              |
| 5841g | Autism    | 12  | 15  | M      | Caucasian | Hanging           | UMBTB               |

PMI, postmortem interval.

Known medications:

aTegretol, Phenobarbital, Theodor.
bRanitidine, Hydrocodone, Lamictal, Proferin, Aranesp, Zonegran, Diovian, Microgestin.
cNeurontin, Risperidone, Lorazepam, Oxcarbazepine.
dKepra, Lexapro, Biaxin.
eClonidine, Melatonin, Trileptal, Zoloft.
fKepra.
gDaytrana, Vyvanse.

Table 2 Multiple concentration binding conditions for serotonin receptor tritiated ligand binding in the ACC, PCC, and FG

| Receptor | Ligand | KD (nM) | Concentrations (nM) | Incubation | Displacer | Exposure (weeks) |
|----------|--------|---------|---------------------|------------|-----------|-----------------|
| 5-HT2    | [3H] Ketanserin | 0.5     | 0.53, 1.0, 2.8, 9.4, 32.5, 89.6, 116.0 | 30 min  | Imipramine | 3–24            |
| 5-HTT    | [3H] Citalopram  | 3.0    | 0.51, 1.4, 3.6, 7.8, 30.6, 89.2, 127.0 | 1 h       | Ritanserin | 5–24            |
| 5-HT1A   | [3H] 8-OH-DPAT   | 2.0    | 0.53, 1.5, 2.9, 10.7, 29.1, 91.0, 138.9 | 1 h       | 5-HT Hydrochloride | 4–26            |

5-HT, 5-hydroxytryptamine (serotonin); 5-HTT, serotonin transporter; ACC, anterior cingulate cortex; FG, fusiform gyrus; PCC, posterior cingulate cortex.
between autism and control groups. As we used all available tissue obtained from the respective brain banks, a power analysis was not carried out and no tests for outliers were conducted.

**Results**

Each of the three cortical regions, ACC, PCC, and FG were included in all three ligands; [3H]-ketanserin (5-HT2), [3H]-citalopram (5-HTT), and [3H]-8-OH-DPAT (5-HT1A). The superficial (Lamina I–III in ACC; I–V in PCC and FG) and deep layers (Lamina V–VI) were approximately delineated from adjacent Nissl stained sections and autoradiographs as shown in Fig. 1. Anatomical levels were matched as much as possible based on whole tissue blocks provided by the brain banks. The receptor distribution pattern based on the ligand binding was mostly homogeneous with [3H]-ketanserin and [3H]-citalopram across layers, whereas [3H]-8-OH-DPAT had high binding in the superficial layers of the cortex as compared to the deep layers at most ligand concentrations, which saturated at a similar level with higher concentrations of ligand. The autism ACC case shown in Fig. 1 had similar binding to the control case for 5-HT1A, but had lower binding for both 5-HT2 and 5-HTT indicating receptor-specific alterations in the serotonergic system in some autism cases within the ACC.

These alterations are readily observed when comparing saturation binding curves in the ACC for control cases versus autism cases (Fig. 2). There were no group differences when comparing the B\(_\text{max}\) or K\(_D\) of all autism and control cases for 5-HT1A and 5-HT2, however, a decrease in B\(_\text{max}\) for 5-HTT binding was significant for the autism group (Table 3). Intriguingly, when separating total control and autism cases into adults (> 16 years) and children (≤ 16 years) it appears that the adult cases are mostly driving the group decrease in 5-HTT binding. Furthermore, separating analysis of children and adults for 5-HT2 binding revealed a statistically significant decrease in B\(_\text{max}\) for adult autism cases that was not apparent when comparing the autism and control group as a whole. This indicates a similar receptor number in the ACC when comparing controls and children with autism, but a tendency for autism cases to have lower binding levels of 5-HTT and 5-HT2 than controls in adulthood.

While the separation of children and adults mirrors clinical studies, the cutoff age of 16 years isn’t necessarily biologically relevant, as development occurs over a continuous time course. Therefore, further analyses were carried out to more clearly define the relationship between age and 5-HT receptor expression. Plotting B\(_\text{max}\) values against age (Fig. 3) reveal similar slopes for 5-HTT density (\(p = 0.94\)), but an intercept (elevation) that is significantly lower in the autism group across ages (\(p = 0.025\)). 5-HT2 density increases with age in control cases, whereas in autism there is a decrease with age and significantly different slopes between regression lines (\(p = 0.032\)).

The results from the three ligands and three cortical regions also indicate that disruptions in the serotonergic system are region specific. There were no differences in B\(_\text{max}\) or K\(_D\) for any ligand in the PCC or FG (see Figures S1, S2; Tables S1, S2). There were not enough female cases in the cohort to analyze differences between gender; however, the two female cases (1401 and 5771) in the adult autism group of the ACC had B\(_\text{max}\) values that fell in the normal range of controls but higher values of the autism group, suggesting the need to analyze a larger cohort to determine if this decrease in serotonin receptors is gender specific for males.

Since some of the autism cases had a history of at least one seizure, Welch’s t-tests were conducted to compare the B\(_\text{max}\) means for each ligand between autism cases with a seizure history and without. There were no statistical differences in
### Anterior Cingulate Cortex

#### Deep Layers

| CASES | [3H] Ketanserin | [3H] Citalopram | [3H] 8OH-DPAT |
|-------|----------------|----------------|-------------|
|       | B<sub>max</sub> | pKD            | B<sub>max</sub> | pKD            | B<sub>max</sub> | pKD            |
| Children | 4103 | 1811 | 7.50 | 735.3 | 6.78 | 197.6 | 7.24 |
|          | 4104 | 1205 | 7.81 | 218.2 | 7.22 |
|          | 4267 | 2088 | 7.41 | 211.3 | 7.53 | 306.0 | 6.82 |
|          | 4268 | 4224 | 6.85 | 846.5 | 6.68 | 294.0 | 6.70 |
|          | 4271 | 590.2 | 7.76 | 596.5 | 6.31 | 263.6 | 7.02 |
|          | 4272 | 2277 | 7.44 | 479.2 | 7.03 | 227.8 | 7.10 |
|          | 4275 | 1025 | 7.85 | 201.8 | 7.24 | 89.2 | 7.85 |
|          | 4345 | 4241 | 6.83 | 289.1 | 7.03 | 1025 | 7.38 |
|          | 4364 | 2130 | 7.37 | 166.9 | 7.63 | 163.1 | 7.14 |
|          | 4599 | 2676 | 7.32 | 488.9 | 6.96 | 185.9 | 7.35 |
|          | 5813 | 1219 | 7.76 | 170.2 | 7.17 | 676.3 | 6.62 |
| Mean    | 2135 | 7.45 | 418.6 | 7.04 | 225.6 | 7.14 |
| ±SEM    | 364 | 0.11 | 78.6 | 0.12 | 45.9 | 0.11 |

#### Superficial Layers

| CASES | [3H] Ketanserin | [3H] Citalopram | [3H] 8OH-DPAT |
|-------|----------------|----------------|-------------|
|       | B<sub>max</sub> | pKD            | B<sub>max</sub> | pKD            | B<sub>max</sub> | pKD            |
| Children | 1078 | 767.8 | 7.35 | 249.3 | 6.75 | 327.4 | 6.71 |
|          | 1401 | 1158 | 7.73 | 204.1 | 6.90 | 183.0 | 7.14 |
|          | 1484 | 1466 | 7.66 | 170.0 | 7.39 | 319.4 | 6.95 |
|          | 1664 | 745.6 | 7.75 | 202.7 | 6.80 | 304.1 | 7.06 |
|          | 3845 | 1601 | 7.48 | 186.9 | 7.72 | 80.1 | 7.83 |
|          | 5574 | 1474 | 7.80 | 302.8 | 7.36 | 520.5 | 6.68 |
|          | 5754 | 1265 | 7.80 | 274.1 | 7.23 | 630.2 | 6.27 |
|          | 5771 | 1573 | 7.71 | 303.4 | 7.03 | 518.0 | 6.79 |
|          | 5864 | 1295 | 7.47 | 237.6 | 7.41 | 297.1 | 7.11 |
| Mean    | 1261 | 7.64 | 236.8 | 7.18 | 353.3 | 6.95 |
| ±SEM    | 107 | 0.05 | 16.5 | 0.11 | 58.1 | 0.14 |
| T-test | *0.0402 | 0.1502 | *0.0475 | 0.4105 | 0.2055 | 0.2857 | *0.0489 | 0.2687 | *0.0497 | 0.3769 | 0.1068 | *0.0479 |

© 2019 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
### Table 3 (continued)

#### Anterior Cingulate Cortex

| Cases | Deep Layers |    | Superficial Layers |    |
|-------|-------------|----|--------------------|----|
|       | [3H] Ketanserin | [3H] Citalopram | [3H] 8OH-DPAT | [3H] Ketanserin | [3H] Citalopram | [3H] 8OH-DPAT |
|       | Bmax | pKD | Bmax | pKD | Bmax | pKD | Bmax | pKD | Bmax | pKD | Bmax | pKD |
| Children | 1848 | 7.55 | 314.5 | 6.81 | 160.4 | 7.68 | 1751 | 7.60 | 413.9 | 6.65 | 229.3 | 7.93 |
| Mean   | 1812 | 7.43 | 379.5 | 7.03 | 245.1 | 7.30 | 1711 | 7.48 | 363.6 | 7.05 | 235.0 | 7.73 |
| ±SEM   | 233  | 0.13 | 69.9  | 0.13 | 36.0  | 0.12 | 199  | 0.12 | 58.6  | 0.14 | 18.9  | 0.10 |
| 1469   | 695.3 | 7.78 | 123.4 | 7.33 | 806.3 | 6.10 | 725.3 | 7.76 | 124.9 | 7.30 | 323.0 | 6.59 |
| 3924   | 2314 | 7.37 | 144.0 | 7.32 | 315.5 | 6.69 | 2320 | 7.39 | 148.5 | 7.29 | 231.7 | 7.64 |
| 4334   | 1344 | 7.83 | 169.2 | 7.49 | 106.6 | 7.99 | 1399 | 7.81 | 176.2 | 7.48 | 160.2 | 8.20 |
| 4721   | 2789 | 7.18 | 662.4 | 6.56 | 334.1 | 6.95 | 2793 | 7.19 | 568.2 | 6.66 | 248.1 | 7.67 |
| 5302   | 2369 | 7.30 | 228.7 | 7.03 | 158.2 | 7.48 | 2104 | 7.41 | 224.7 | 7.05 | 193.6 | 7.90 |
| 5565   | 1700 | 7.72 | 381.9 | 7.18 | 592.3 | 6.60 | 1711 | 7.73 | 375.0 | 7.25 | 216.6 | 7.53 |
| Mean   | 2045 | 7.43 | 259.16 | 7.15 | 306.37 | 7.19 | 2056.4 | 7.44 | 299.17 | 7.12 | 213.82 | 7.71 |
| ±SEM   | 269  | 0.12 | 60.7  | 0.09 | 81.6  | 0.21 | 289  | 0.13 | 51.8  | 0.09 | 21.5  | 0.16 |
| T-test | 0.5229 | 0.9940 | 0.2140 | 0.4462 | 0.5062 | 0.6723 | 0.3423 | 0.8641 | 0.2020 | 0.6483 | 0.4701 | 0.9038 |
| T-test all cases | control vs autism | 0.2339 | 0.3763 | 0.0174 | 0.2488 | 0.1807 | 0.3654 | 0.5145 | 0.6474 | 0.0162 | 0.3228 | 0.3930 | 0.1479 |

ACC, anterior cingulate cortex.

T-tests were performed as described in methods to compare autism (orange) to controls (black) within groups of adults only, children only, and total cases. Asterisks mark significantly different group means.
Fig. 2 Individual saturation binding curves for all cases in the ACC. Individual curves each include seven concentrations of ligand. Autism (orange) cases had significantly decreased binding in both superficial and deep layers for 5-HTT ([3H]-citalopram) compared to control cases (black) that is driven by a lower $B_{\text{max}}$ in adult autism cases. Similarly, 5-HT2 ([3H]-ketanserin) receptor binding ($B_{\text{max}}$) was decreased in adult cases ($n = 11$ control and 9 autism), but not in children ($n = 8$ control and 9 autism). 5-HT1A ([3H]-8-OH-DPAT) binding was unchanged for each of the three groups; total autism and control cases, adults only and children only. $n$ = individual postmortem cases. ACC, anterior cingulate cortex; 5-HT, 5-hydroxytryptamine (serotonin).
group means in the ACC autism cases for neither [3H]-ketanserin (seizure mean = 2026 ± 376.6, no seizure mean = 1520 ± 177.0, \( p = 0.26 \)), [3H]-citalopram (seizure mean = 187.3 ± 31.91, no seizure mean = 279.7 ± 34.44, \( p = 0.07 \)) nor [3H]-8-OH-DPAT (seizure mean = 224.6 ± 34.53, no seizure mean = 260.1 ± 24.62, \( p = 0.42 \)). For the two ligands showing significant differences in autism, \( B_{max} \) means were not different based on source of the tissue (ATP vs. UMBTB Table 1), as [3H]-ketanserin \( p = 0.09 \) and [3H]-citalopram \( p = 0.53 \). There was also no correlation of \( B_{max} \) values to postmortem interval (Figure S3).

Although the number of autism cases with ADI-R scores available was limited for tissue obtained from the ACC, when plotting against \( B_{max} \) values (Fig. 4) a significant relationship between expression and symptom severity was observed for 5-HTT (\( R^2 = 0.9839 \)), but not for 5-HT\(_2\) expression (\( R^2 = 0.2234 \)).

**Discussion**

Given the longstanding implications of 5-HT dysfunction in ASD and common use of SSRIs to ameliorate adverse behaviors, it is important to determine which receptor subtypes may contribute to ASD symptoms and thus be amenable to pharmacological intervention within the central nervous system. In the present study, the ASD cohort from the PCC and FG displayed normal density and ligand affinity for 5-HT\(_1A\), 5-HT\(_2\), and 5-HTT. However, in the ACC, while the 5-HTT assay showed significant density decreases within the entire autism group (adults and children), this difference was most prominent in the adult autism cases, since the group of children mean 5-HTT density remained unchanged. However, age regression analysis showed a consistent reduction in 5-HTT across ages, as indicated by a lower elevation of the regression line. Whole group 5-HT\(_2\) density was not altered in autism, however, when analyzing children

---

**Fig. 3 Age regression analysis.** Receptor expression (\( B_{max} \)) plotted against age for both [3H]-ketanserin (5-HT\(_2\)) and [3H]-citalopram (5-HTT) in the ACC. [3H]-ketanserin had a decreasing slope in the autism group (\( n = 18 \)) that was significantly different (\( p = 0.032 \)) from controls (\( n = 19 \)). [3H]-citalopram had no difference in slope (\( p = 0.94 \)), but had a significantly lower intercept (elevation) compared to controls (\( p = 0.025 \)). \( n \) = individual postmortem cases. ACC, anterior cingulate cortex; 5-HT, 5-hydroxytryptamine (serotonin).

**Fig. 4 Symptom severity compared to receptor expression.** Receptor expression (\( B_{max} \)) plotted against autism diagnostic interview-revised (ADI-R) scores (\( n = 6 \)) with \( R^2 \) values given. Higher ADI-R scores represent increased severity of autism symptoms. \( n \) = individual postmortem autism cases.
and adults separately, the adult ACC autism cases again show significantly decreased density of 5-HT2 receptors. Furthermore, 5-HT2 receptor expression increased with age in controls, but decreased with age in autism. This demonstrates age-dependent differences in 5-HT within the ACC in a subset of ASD individuals. These findings are particularly intriguing in light of the clinical efficacy of SSRI use. SSRI drugs are commonly administered to individuals with autism, as up to 80% of children with ASD experience clinically significant anxiety (Muris et al. 1998; Leyfer et al. 2006; Simonoff et al. 2008). Nadeau et al. (2011) concluded, in a review of treatment studies, that cognitive-behavior therapies may be more helpful than SSRI administration in youth with ASD. As reaffirmed in the 2013 Cochrane Review (Williams et al. 2013), there is no conclusive evidence that children benefit from SSRIs, but have been shown in major clinical trials to have significant adverse outcomes (e.g. King et al. 2009) in contrast to some adults with autism that do benefit from SSRIs. Our data parallels this information in that only a subset of adults with autism (> 16 years of age) have decreased density of 5-HT2 and 5-HTT in the ACC, but children appear to have normal levels in all three cortical regions evaluated. It remains to be explored whether there are similar 5-HT receptor deficits in other brain regions in autism or whether the ACC is a more susceptible area than other cortical brain regions.

A possible explanation for inconsistent results within the literature regarding the 5-HT system in ASD is the heterogeneity inherent to the condition amidst small sample sizes. For example, genetic polymorphisms in the 5-HT transporter have been implicated in ASD (Yonan et al. 2003; Devlin et al. 2005; Sutcliffe et al. 2005; Kistner-Griffin et al. 2011; Najjar et al. 2015), however, it is only a subset of individuals, presuming the majority of ASD cases do not show genetic differences in 5-HTT. Furthermore, most imaging studies involving ASD, as discussed in the introduction, focus on high-functioning individuals that may not be representative of the entire autism spectrum. The data presented here show mean decreases in receptor density in superficial and deep layers of the ACC in the adult autism groups, but several autism cases fall within the normal control range, indicating that not every autism case shows differences in specific 5-HT receptor subtypes in the examined areas. Furthermore, while hyperserotonemia is considered the best replicated biomarker in autism, it still represents less than half of the ASD population (Gabriele et al. 2014). For these reasons, treatments for ASD should be tailored to the individual. As tests for peripheral hyperserotonemia and genetic variants become more widely available, future studies evaluating the efficacy of SSRIs in autism should divide individuals into subgroups based on evidence of 5-HT disruption. As demonstrated by the data presented and by clinical SSRI outcomes, age of the individual may be a key factor for positive clinical outcomes, however, not all studies divide cohorts by age. For example, in a 6-week open label trial with 44 participants with autism, two increasing daily doses of the SSRI escitalopram resulted in improvement on insistence of sameness and irritability symptoms irrespective of whether individuals had polymorphisms of 5-HTT (SLC6A4) or of the 5-HT2A receptor (HTR2A). However, differences in age groups were not reported despite subjects in the study falling between 5 and 44 years old (Najjar et al. 2015). Interestingly, symptom severity was correlated with 5-HTT expression, but not with 5-HT2 receptor expression. Higher ADI-R scores represent increased symptom severity, which was correlated with higher 5-HTT expression in a subset of autism cases in which ADI-R scores were available. It is not clear why higher expression would be correlated with symptom severity, as control cases have higher expression. However, the expression of 5-HTT is dependent on a diverse set of mechanisms (Daws and Gould 2011). As 5-HTT is the uptake site of 5-HT, its regulation is dependent on 5-HT expression. If there is an increase in brain serotonin (central hyperserotonemia), a downregulation of 5-HTT would help to offset its effects and if individuals were unable to downregulate 5-HTT (due to a polymorphism or other reason), that heightened 5-HT within the brain could be associated with more severe autistic symptoms. Further research is needed to clarify the development of the serotonergic system in autism, particularly in how receptors respond to altered levels of 5-HT during development of the brain. The results of the present study also suggest that 5-HT dysfunction may be secondary to other mechanisms or emerge as a compensation pattern within disrupted circuits. As suggested by our data, if the 5-HTT reductions begin in childhood, it is possible that the reductions in 5-HT2 in adults are occurring in response to this initial deficit. Further studies that evaluate changes in 5-HT in ASD with age will be needed to determine whether children that have normal levels of 5-HT receptors at a young age present with deficits later in life or whether these individuals had 5-HT alterations throughout development. Since there were no differences in ligand binding affinity across each cortical region and ligand, it is unlikely our cohort had significant genetic risk in relationship to 5-HT1A, 5-HT2A, or 5-HTT, which would again indicate a compensation pattern of 5-HT alterations instead of a primary 5-HT causative factor.

As individuals with ASD are commonly prescribed SSRIs at a young age, the need for informed use of pharmacological interventions is warranted. Our data adds to the growing literature that caution should be taken toward SSRIs in children under the age of 16 and that the 5-HT system can be altered within distinct cortical regions and receptor subtypes.

The ACC has consistent neurochemical, cytoarchitectural, and connectivity differences in adults with idiopathic autism

An intriguing result of the present study is the selective vulnerability of the ACC versus the PCC or FG due to changes in binding of 5-HT2 receptors and 5-HTT only in the
ACC. Previous studies identified cytoarchitectural changes, including increased packing density, in ACC subregions and increased neurons in the white matter just below layer VI in about half of the adult autism postmortem cases in the study (Simms et al. 2009). A multimodal imaging study found that the ACC cytoarchitectural changes related to symptom severity in individuals with neurodevelopmental conditions including autism (Forde et al. 2018). In a recent landmark postmortem study of ACC connectivity, Zikopoulos et al. (2018) demonstrated an increased proportion of thin axons in the white matter just below the ACC from childhood through adulthood, which was indicative of hyper-connectivity to short range neighboring cortices and a decreased proportion of thick diameter axons below the ACC, representing hypo-connectivity of long range cortical connectivity.

Neurochemical differences in the autism ACC have been reported by Oblak et al. (2009, 2010). These authors reported significant decreases in GABA-ARs and GABA-BRs in the ACC in adult postmortem autism cases in superficial (I–III) and deep layers (V–VI). A recent proton magnetic resonance spectroscopic study by Ito et al. (2017) reported hypoGABAergic alterations in children with autism, but normal glutamate markers suggesting that the ACC may contribute to excitatory/inhibitory imbalance in subjects with idiopathic autism.

Using cognitive measures, behavioral analysis, and functional magnetic resonance imaging tasks in adults with idiopathic autism, Balsters et al. (2017) concluded that the ACC is a critical component of social behavior and that socially-specific prediction errors occurred in the autism group. These authors also concluded that connectivity between the ventral medial prefrontal cortex and the ACC may represent a neural substrate underlying the social deficits. In fact, ACC activity can be monitored via 5-HT2 receptors in rat pups as early as P10-P12 and is modulated by maternal contact, which increases local field potentials in low frequency bands (Courtiol et al. 2018).

Collectively, these and other studies demonstrate that the ACC is a critical node for a variety of high-order functions in the neurotypical brain. In autism, there are both structural changes in cortical lamination in the ACC in early development and through adulthood, as well as neurochemical changes in critical neurotransmitter systems, which includes GABA and serotonin as demonstrated by significant alterations in receptor densities across superficial-deep lamina. This suggests that modulation of both input and output of the principal pyramidal neurons of the ACC may be impacted, potentially resulting in altered short and long-range connectivity differences and affecting a wide range of autism-related behaviors.

**Summary and conclusions**

Some SSRIs administered to individuals with autism reported successful treatment of various symptoms, but citalopram hydrobromide had variable results that included harmful effects when administered to children. Previous studies have reported more favorable results when citalopram was administered to autistic individuals with specific polymorphisms. SSRIs mainly target the serotonin transporter and its blocking action allows 5-HT to persist at the synapse. SSRIs are drugs that typically also affect other 5-HT receptors, as well as dopamine and other receptor types. Multiple concentration ligand binding autoradiography is still a very useful tool to quantify the number ($B_{max}$) and affinity ($K_D$) of a variety of receptor types and was applied to this study investigating whether 5-HTT and other major subtypes of 5-HT receptors (5-HT$_2$ and 5-HT$_1A$) had significant changes in children and/or adult autism cohorts as compared to neurotypically developing individuals. Receptor density ($B_{max}$) changes were seen in $^3$H-citalopram labeled 5-HTT and in $^3$H-ketanserin labeled 5-HT$_2$ receptors in the adult autism group in the ACC only, but not in children. Furthermore, there were no changes in $^3$H-8-OH-DPAT labeled 5-HT$_1A$ receptors in any of the groups or cortices. This study therefore provides further evidence that the ACC is a highly vulnerable region in autism, with changes in a number of receptor types that may contribute to the excitatory/inhibitory imbalance in the autism brain via disruptions in its cytoarchitecture and connectivity with other local and distant cortices. This could potentially have profound effects within cortical networks that, in part, underlie autism-related behaviors.

**Acknowledgments and conflicts of interest disclosure**

This work is supported by NIMH grant number 5R21MH099457 (G.J.B.). Further support is through the Hussman Foundation. Human tissue was obtained from the University of Maryland Brain and Tissue Bank, which is a Brain and Tissue Repository of the NIH NeuroBioBank. Additional tissue was obtained from Autism BrainNet, sponsored by the Simons Foundation and Autism Speaks. The authors also acknowledge the Autism Tissue Program that was the predecessor to Autism BrainNet. The authors gratefully thank Elizabeth Benevides and Dr. John P. Hussman for their helpful comments in reviewing this manuscript. The authors do not have a conflict of interest to declare.

All experiments were conducted in compliance with the ARRIVE guidelines.

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Figure S1.** Individual saturation binding curves for all cases in the PCC.
Figure S2. Individual saturation binding curves for all cases in the FG.

Figure S3. Postmortem interval (PMI) versus receptor binding.

Table S1. B\text{max} \text{and} K_D \text{for each individual PCC case in both deep and superficial layers.}

Table S2. B\text{max} \text{and} K_D \text{for each individual FG case in both deep and superficial layers.}

References

Aman M. G., Lam K. S. L. and Collier-Crespin A. (2003) Prevalence and patterns of use of psychoactive medicines among individuals with autism in the Autism Society of Ohio. J. Autism Dev. Disord. 33, 527–534.

Apps M. A., Rushworth M. F. and Chang S. W. (2016) The anterior cingulate gyrus and social cognition: tracking the motivation of others. Neuron 90, 692–707.

Azmitia E. C., Singh J. S. and Whitaker-Azmitia P. M. (2011) Increased serotonin axons (immunoreactive to 5-HT transporter) in postmortem brains from young autism donors. Neuropharmacology 60, 1347–1354.

Bailey A., Luthert P., Dean A., Harding B., Janota I., Montgomery M., Rutter M. and Lantos P. (1998) A clinicopathological study of autism. Brain 121, 889–905.

Balsters J. H., Apps M. A. J., Bolis D., Lehner R., Gallagher L. and Wenderoth N. (2017) Disrupted prediction errors index social deficits in autism spectrum disorder. Brain 140, 235–246.

Bauman M. and Kemper T. L. (1985) Histoanatomic observations of the brain in early infantile autism. Neurology 35, 866–74.

Chandana S. R., Behen M. E., Juhász C., Muzik O., Rothermel R. D., Mangner T. J., Chakraborty P. K., Chugani H. T. and Chugani D. C. (2005) Significance of abnormalities in developmental trajectory and asymmetry of cortical serotonin synthesis in autism. Int. J. Dev. Neurosci. 23, 171–182.

Chen R., Davis L. K., Guter S., Wei Q., Jacob S., Potter M. H., Cox N. J., Cook E. H., Sutcliffe J. S. and Li B. (2017) Leveraging blood serotonin as an endophenotype to identify de novo and rare variants involved in autism. Mol. Psychiatry 8, 14.

Chevallier C., Kohls G., Troiani V., Brodkin E. S. and Schultz R. T. (2012) The social motivation theory of autism. Trends Cogn. Sci. 16, 231–239.

Chugani D. C., Muzik O., Rothermel R., Behen M., Chakraborty P., Mangner T., da Silva E. A. and Chugani H. T. (1997) Altered serotonin synthesis in the dentatohalamocortical pathway in autistic boys. Ann. Neurol. 42, 666–669.

Chugani D. C., Muzik O., Behen M., Rothermel R., Janisse J. J., Lee J. and Chugani H. T. (2001) Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann. Neurol. 45, 267–295.

Cook E. H. and Leventhal B. L. (1996) The serotonin system in autism. Curr. Opin. Pediatr. 8, 348–354.

Courtier E., Wilson D. A., Shah R., Sullivan R. M. and Teixeira C. M. (2018) Maternal regulation of Pups’ cortical activity: role of serotonergic signaling. eNeuro 5, 1–12.

Daws L. C. and Gould G. G. (2011) Ontogeny and regulation of the serotonin transporter: providing insights into human disorders. Pharmacol. Ther. 131, 61–79.

Dawson G., Webb S. J., Wijsman E. and Schellenberg G. (2005) Neurocognitive and electrophysiological evidence of altered face processing in parents of children with autism: implications for a model of abnormal development of social brain circuitry in autism. Dev. Psychopathol. 17, 679–697.

DeLean A., Hancock A. A. and LeKowitz R. J. (1982) Validation and statistical analysis of a computer modeling method for quantitative analysis of radioligand binding data for mixtures of pharmacological receptor subtypes. Mol. Pharmacol. 21, 5–16.

Devlin B., Cook E. H., Jr, Coon H., et al. (2005) Autism and the serotonin transporter: the long and short of it. Mol. Psychiatry 10, 1110–1116.

Eissa N., Al-Houqani M., Sadeq A., Ojha S. K., Sasse A. and Sadek B. (2018) Current enlightenment about etiology and pharmacological treatment of autism spectrum disorder. Neuropharmacology 12, 304.

Forde N. J., Naaijen J., Lythgoe D. J., Akkermans S. E. A., Van Bourgondien M. E. and Jr Cook E. H. (2011) Parent-of-origin effects of the serotonin transporter gene associated with autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156, 139–144.

Kistner-Griffin E., Brune C. W., Davis L. K., Sutcliffe J. S., Cox N. J. and Jr Cook E. H. (2011) Parent-of-origin effects of the serotonin transporter gene associated with autism. Am. J. Med. Genet. B Neuropsychiatr. Genet. 156, 139–144.

Kolling N., Behrens T., Wittmann M. K. and Rushworth M. F. S. (2016) Multiple signals in anterior cingulate cortex: a review of the literature. Res. Dev. Disabil. 37, 254–289.

Langworthy-Lam K. S., Aman M. G. and Van Bourgondien M. E. (2002) Prevalence and patterns of use of psychoactive medicines in autism spectrum disorder. Arch. Gen. Psychiatry 59, 122–128.

Mol. Psychiatry 7, 583–590.

Neuropharmacology 12, 304.

Multiple signals in anterior cingulate cortex. Curr. Opin. Neurol. 27, 36–43.

Multiple signals in anterior cingulate cortex. Curr. Opin. Neurol. 27, 36–43.

Multiple signals in anterior cingulate cortex. Curr. Opin. Neurol. 27, 36–43.
individuals with autism in the Autism Society of North Carolina. *J. Child Adolesc. Psychopharmacol.* 12, 311–321.
Laubach M., Caiano M. S. and Narayanan N. S. (2015) Mistakes were made: neural mechanisms for the adaptive control of action initiation by the medial prefrontal cortex. *J. Physiol. Paris* 109, 104–117.
Leyfer O. T., Folstein S. E., Bacalman S., Davis N. O., Dinh E., Morgan J., Tager-Flusberg H. and Lainhart J. E. (2006) Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. *J. Autism Dev. Disord.* 36, 849–861.
Luchelli J. P. and Bertschy G. (2018) Low-dose fluoxetine in four children with autistic spectrum disorder improves self-injurious behavior, ADHD-like symptoms, and irritability. *Case Rep. Psychiatry* 2018, 827850.
Makkonen I., Riikonen R., Kokki H., Airaksinen M. M. and Kuikka J. T. (2008) Serotonin, and dopamine transporter binding in children with autism determined by SPECT. *Dev. Med. Child Neurol.* 50, 593–597.
McDougall C. J., Naylor S. T., Cohen D. J., Volkmar F. R., Heninger G. R. and Price L. H. (1996) A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. *Arch. Gen. Psychiatry* 53, 1001–1008.
Montgomery A. K., Shuffrey L. C., Guter S. J., Laubach M., Caetano M. S. and Narayanan N. S. (2015) Mistakes were made: neural mechanisms for the adaptive control of action initiation by the medial prefrontal cortex. *J. Physiol. Paris* 109, 104–117.
Muller C. L., Anacker A. M. J. and Veenstra-VanderWeele J. (2016) The 5-HT2A receptor in autism spectrum disorder: from biomarker to translational social-orienting model of autism. *J. Anxiety Disord.* 39, 125–141.
Nichols D. E. and Nichols C. D. (2008) Serotonin receptors. *J. Neurochem.* 108, 1614–1641.
Oblak A., Gibbs T. T. and Blatt G. J. (2009) Decreased GABA\(_A\) receptors and benzodiazepine binding sites in the anterior cingulate cortex in autism. *Autism Res.* 2, 205–219.
Oblak A. L., Gibbs T. T. and Blatt G. J. (2010) Decreased GABA\(_B\) receptors in the cingulate cortex and fusiform gyrus in Autism. *J. Neurochem.* 114, 1414–1423.
Oblak A., Gibbs T. T. and Blatt G. J. (2011) Reduced GABA\(_A\) receptors and benzodiazepine binding sites in the posterior cingulate cortex and fusiform gyrus in autism. *Brain Res.* 1380, 218–228.
Oblak A., Gibbs T. T. and Blatt G. J. (2013) Reduced serotonin receptor subtypes in a limbic and a neocortical region in autism. *Autism Res.* 6, 571–583.
Oswald D. P. and Sonenklar N. A. (2007) Medication use among children with autism spectrum disorders. *J. Child Adolesc. Psychopharmacol.* 17, 348–355.
Pratt L. A., Brody D. J. and Gu Q. (2017) Antidepressant use among persons aged 12 and over: United States, 2011–2014. *NCHS Data Brief* 283, 1–8.
Rushworth M. F. S., Kolling N., Sallet J. and Mars R. B. (2012) Valuation and decision-making in frontal cortex: one or many serial or parallel systems? *Curr. Opin. Neurobiol.* 22, 946–955.
Schain R. J. and Freedman D. X. (1961) Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. *J. Pediatr.* 58, 315–320.
Schultz R. T. (2005) Developmental deficits in social perception in autism: the role of the amygdala and fusiform face area. *Int. J. Dev. Neurosci.* 23, 125–141.
Simonoff E., Pickles A., Charman T., Chandler S., Loucas T. and Baird G. (2008) Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. *J. Am. Acad. Child Adolesc. Psychiatry* 47, 921–929.
Sutcliffe J. S., Delahanty R. J., Prasad H. C., McCauley J. L., Han Q., Jiang L., Li C., Folstein S. E. and Blakely R. D. (2005) Allelic heterogeneity at the serotonin transporter locus (5SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. *Am. J. Hum. Genet.* 77, 265–279.
Ulstrup M., Fischer A. G., Nigbur R. and Endrass T. (2014) Neural mechanisms and temporal dynamics of performance monitoring. *Trends Cogn. Sci.* 18, 259–267.
Verguts T., Vassena E. and Silvetti M. (2015) Adaptive effort investment in cognitive and physical tasks: a neurocomputational model. *Front. Behav. Neurosci.* 9, 57.
Williams K., Brignell A., Randall M., Silove N. and Hazell P. (2013) Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). *Cochrane Database Syst. Rev.* (8), CD004677.
Yonan A. L., Alarcón M., Cheng R., et al. (2003) A genomewide screen of 345 families for autism-susceptibility loci. *Am. J. Hum. Genet.* 73, 886–897.
Zikopoulos B., Liu X., Tepe J., Trutzer I., John Y. J. and Barbas H. (2018) Opposite development of short- and long-range anterior cingulate pathways in autism. *Acta. Neuropathol.* 136, 759–778.